Want access to unlimited case records and advanced research tools? Create your free CasePortal account now. No credit card required to register.
Try CasePortal for FreeJ. Wilkinson finds the lower court properly granted summary judgment to the agency. Under the Medicaid Drug Rebate Program, a drug manufacturer that increases its prices faster than inflation rises must reimburse Medicaid for the difference. These reimbursements are paid via rebates. Primarily, each drug’s rebate amount is usually determined based on its own original price and inflation clock, but not always. Congress has instructed in the Medicaid statute that some “line extension” drugs can be on the hook not only for their own price increases but also for the price increases of the drugs they evolved from. The agency promulgated a regulation that set forth criteria for what constitutes a line-extension drug that the pharmaceutical company claims expanded the definition of a line extension beyond what the Medicaid statute permitted. Each departure of the regulatory text is patently superficial, with no discernable effect on the term’s reach. Affirmed.